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Abstract
Background: With chronic infection, hepatitis C virus (HCV) RNA can be detected in B cells and
associated with B-cell disorders, but these are not well defined.
Methods: The relationship between HCV infection and lymphocyte subpopulations was evaluated
rigorously in 120 asymptomatic hemophilic patients, randomly selected from a prospective cohort
study. CD4+ T cells, CD8+ T cells, CD19+ B cells, and CD56+ NK cells were quantified by flow
cytometry using cryopreserved peripheral blood mononuclear cells of 24 hemophilic patients in
each of five age-matched groups [uninfected; chronic HCV with or without human
immunodeficiency virus (HIV); and cleared HCV with or without HIV].
Results: As expected, patients with HIV had significantly reduced CD4+ and increased CD8+ T
cells. Irrespective of HIV, patients with chronic HCV infection had approximately 25% fewer
CD19+ B cells than those without chronic HCV infection.
Conclusions: These data support the hypothesis that asymptomatic patients with chronic HCV
infection have an altered B-lymphocyte population.
Background
The natural history of hepatic C virus (HCV) infection
may include B-cell diseases. HCV can be detected in
peripheral blood mononuclear cells (PBMCs) and may
also replicate in these cells [1-3]. Type II cryogloblinemia
and some non-Hodgkin lymphomas have been linked to
HCV [4], but links between B cells and asymptomatic
HCV infection are poorly defined.
One study reported that hemophilic patients co-infected
with HCV and human immunodeficiency virus (HIV) had
reduced B cells and CD4+ T cells [5]. To further character-
ize PBMC immunophenotypes in patients with chronic or
cleared HCV infection, we quantified proportions of
CD4+ T cells, CD8+ T cells, B cells, and natural killer (NK)
cells in PBMCs of carefully selected, well characterized
hemophilic patients.
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Study subjects
Patients with hemophilia or another congenital coagula-
tion disorder (herein referred to as "hemophilia")
enrolled in the Multicenter Hemophilia Cohort Study
[6,7] were categorized into five groups: no HIV or HCV
infection (HIV-/HCV-); chronic (viremic) HCV infection
without HIV (HIV-/HCV RNA+); chronic (viremic) HCV
infection with HIV (HIV+/HCV RNA+); cleared (non-
viremic) HCV infection without HIV (HIV-/HCV RNA-);
and cleared (non-viremic) HCV infection with HIV
(HIV+/HCV RNA-). From each of the five categories, 24
age-matched subjects were randomly selected. Non-
viremic subjects were considered to have cleared HCV
spontaneously, as they were selected from among all
those who, without specific therapy, were negative for
HCV RNA in two specimens collected at least 6 months
apart. Viremic subjects were selected from among all those
with an HCV RNA level above the 67th percentile of all
HCV-positive MHCS patients (described below), all of
whom had received HCV-contaminated plasma products
many years earlier and thus were considered to have
chronic HCV infection. All samples were taken before
1996, the year when highly active antiretroviral therapy
(HAART) became available for treatment of HIV infection.
HCV and HIV assays
HIV status was defined by antibody testing with licensed
immunoassays and immunoblot confirmation. HCV anti-
body status was determined with a commercially availa-
ble second- or third-generation enzyme immunoassay,
with most of the reactive samples confirmed by recom-
binant immunoblot assay (HCV RIBA2.0 or 3.0, Chiron
Corp., Emeryville CA). HCV RNA was detected and viral
load was determined with branched-DNA technology
[Quantiplex HCV RNA 2.0 Assay (bDNA), Chiron Corp.,
Emeryville CA] with a lower limit of sensitivity of 200,000
genome equivalents/mL, which is 31,746 international
units (IU)/mL. HIV-1 viral load was determined with the
HIV Amplicor Monitor (Roche Molecular Diagnostics,
Branchburg, NJ).
Flow cytometry
A vial of 5 million cryopreserved PBMCs, stored in vapor
phase LN2 until testing, was analyzed by flow cytometry
for proportions of CD4+, CD8+, CD19+, and CD56+ cells.
In a biological safety cabinet, vials were thawed in a 37°C
water bath with agitation. To each, 300 units of DNase I
(Rnase-free, Roche Molecular Biochemicals) was added.
The contents were transferred to a 15 ml polypropylene
tube. Thawed cells were slowly diluted with RPMI-1640
media supplemented with 20% fetal calf serum, mixed
frequently, then pelleted at 1000 rpm in a Sorvall RT6000
refrigerated centrifuge. The liquid was decanted. Cells
were mixed in residual volume by gentle shaking, washed
a second time with 4.0 ml of thawing media, then resus-
pended in 2.0 ml calcium- and magnesium-free Dul-
becco's phosphate buffered saline (PBS) containing 4%
heat-inactivated human AB serum to block high affinity Fc
receptors. After 10 minutes the cells were pelleted in the
centrifuge, then resuspended in 0.6 ml of PBS/2% BSA.
100 µl of cell suspension was added to each of five 12 mm
× 75 m polypropylene tubes containing three-color com-
binations of fluorescently tagged monoclonal antibodies
(CD45/CD14/CD3, CD45/CD4/CD3, CD45/CD8/CD3,
CD45/CD19/CD3 and CD45/CD56/CD3). The lym-
phocyte gate was defined with light scatter properties and
CD45/CD14/CD3. A Coulter XL flow analyzer was used
with stops set to collect 5,000 CD3+ lymphocytes in each
sample, if possible. Listmode files were analyzed offline
using Coulter System II software (version 3.0). Quality
control criteria included purity of gated lymphocytes; per-
centage recovery of lymphocytes in the gate; reproducibil-
ity of CD3 between tubes (range <4%); and sum of CD3+,
CD3-/CD19+, CD3-/CD56+ (range 90–110%).
Statistical analysis
The primary analysis was performed on proportions,
rather than absolute levels, of each PBMC subset, to
reduce variance that results from counting total lym-
phocytes in peripheral blood [8]. The Kruskal-Wallis and
Wilcoxon rank sum tests were used to compare the lym-
phocyte subsets between groups, particularly chronic ver-
sus cleared HCV. Statistical analyses were done with the
Statistical Analysis System version 6.0 (Cary, NC).
Results
Characteristics of study subjects
Of the 120 patients, 78 had hemophilia A (factor VIII defi-
ciency). Because patients with hemophilia A generally
required more intensive clotting factor replacement ther-
apy as well as product (Factor VIII concentrate) that was
more infectious for HIV than was Factor IX concentrate
used for patients with hemophilia B, hemophilia A was
significantly more common in the two groups with HIV
co-infection (n = 19 with chronic HCV and n = 21 with
cleared HCV) than the three groups without HIV co-infec-
tion (n = 11 to 14, p = 0.01). By design, the five groups
had similar ages (mean 26.5 years, range 3.4 – 54.8 years,
Table 1). HCV RNA levels were higher with HIV co-infec-
tion (median 4.6 × 106 IU/mL) than with HCV only
(median 2.4 × 106 IU/mL, P < 0.01). Among 48 HIV-
infected subjects, 6 (25%) with cleared and 7 (29%) with
chronic HCV had clinically defined AIDS (P = 0.75) when
their PBMCs were collected for this study. HIV viral load
did not differ between the nine with cleared and the eight
with chronic HCV who were tested on the date PBMCs
were isolated (P = 0.89). Ten of 120 subjects were chroni-
cally infected with hepatitis B virus, and the prevalence of
chronic HBV infection did not differ among 5 groups (P =Page 2 of 5
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cleared HCV infection and one with chronic HCV infec-
tion, had developed ascites, a manifestation of hepatic
decompensation, at the time that their PBMCs were col-
lected for this study.
CD4+ T cells
As expected, subjects with HIV had lower proportions of
CD4+ T cells whether they had cleared HCV (12.4% vs.
40.1%) or chronic HCV (15.3% vs. 41.4%, P#0.0001;
Table 1). Patients with cleared versus chronic HCV, how-
ever, had similar proportions of CD4+ T cells, regardless of
HIV status (P∃0.82).
CD8+ T cells
CD8+ T cells differences mirrored those of CD4+ T cells
(Table 1). Subjects with HIV had higher proportions of
CD8+ T cells whether they had cleared HCV (52.3% vs.
26.0%) or chronic HCV (55.1% vs. 29.1%, P#0.0001).
Regardless of HIV, subjects with cleared and with chronic
HCV had similar proportions of CD8+ T cells (P∃0.30).
CD19+ B cells
Proportions of CD19+ B cells differed significantly among
the five groups (Kruskal-Wallis P = 0.04; Table 1). In pair-
wise comparisons, CD19+ B cells were significantly lower
with HIV and chronic HCV infections compared to unin-
fected subjects (11.4% vs.15.5%, P = 0.03). CD19+ B cells
also were lower, albeit not significantly, with chronic HCV
than with cleared HCV infection in both HIV-uninfected
(13.3% vs. 17.8%, P = 0.09) and HIV-coinfected (11.4%
vs. 15.4%, P = 0.08) groups. CD19+ B-cell levels did not
differ between uninfected subjects and those with cleared
HCV infection (P = 0.63).
CD19+ B-cell proportions did not correlate with HCV viral
load (Spearman R = 0.06, P = 0.78).
CD56+ NK cells
Proportions of CD56+ NK cells did not differ significantly
among the five groups (Kruskal-Wallis P = 0.22; Table 1),
suggesting that HCV infection status of hemophilia
patients had limited effect on CD56+ NK cells.
Discussion
Among HIV-infected subjects, we found that CD19+ B-cell
proportion was statistically significantly lower, from
15.5% to 11.4%, with chronic HCV infection, a fractional
reduction of one-quarter [(15.5–11.4)/15.5 = 0.26]. We
found subjects with chronic HCV without HIV co-infec-
tion had a reduction of the same magnitude, albeit of
marginal statistical significance. HIV infection was more
frequent with hemophilia A than with other coagulation
disorders [6], but this did not confound the association of
HCV chronicity with lower B-cell proportions. In addi-
tion, we observed an approximately one-quarter reduc-
tion (25%) in estimated absolute B-cell count in chronic
HCV, despite higher variance (data not presented) [8].
Overall, our results corroborate and are of similar magni-
tude to those reported from Japan by Yokozaki et al [5].
Infection of B cells by HCV is controversial. Both B cells
and hepatocytes express CD81, a possible receptor for
HCV [9]. If HCV can replicate in B cells, as implied by
detection of negative-strand RNA [10,11], then one might
postulate HCV-related pathogenesis or apoptosis, as
observed in B-cell lines [12]. B-lymphocytopenia also
could occur during initial HCV infection and contribute
to HCV chronicity by impairing neutralizing antibody
Table 1: Age and peripheral blood mononuclear cell subsets (median, interquartile range) by viral infection status.
Viral Infection Statusa















(n = 24) (n = 24) (n = 24) (n = 24) (n = 24)
Age (years) 24.4 (10.8–38.7) 26.7 (18.6–34.0) 25.6 (20.9–31.0) 22.5 (15.8–30.4) 30.0 (17.0–34.7) 0.80
CD4+ (%) 40.4 (35.5–49.2) 12.4 (2.7–27.0) 15.3 (2.3–24.4) 40.1 (34.4–45.7) 41.4 (36.2–45.8) <0.0001
CD8+ (%) 26.3 (24.4–33.0) 52.3 (42.6–59.5) 55.1 (49.2–62.6) 26.0 (20.4–32.8) 29.1 (22.3–37.6) <0.0001
CD19+ B (%) 15.5 (12.6–21.7) 15.4 (10.5–22.2) 11.4 (4.7–15.7) 17.8 (13.7–22.2) 13.3 (10.7–19.5) 0.04
CD56+ NK (%) 9.0 (6.8–12.9) 7.0 (3.7–9.7) 6.5 (4.1–13.8) 9.7 (6.7–13.5) 8.4 (6.5–12.4) 0.22
a HIV, human immunodeficiency virus; HCV, hepatitis C virus; RNA, presence or absence of HCV viremia, as detected by branched DNA assay 
(median HCV viral loads 4.6 × 106 and 2.4 × 106 IU/mL in HIV+ and HIV- subjects, respectively).
b ANOVA test for comparison of age and Kruskal-Wallis test for comparisons of cell proportions.Page 3 of 5
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region-1 [13].
We found no differences in proportions of CD56+ NK cells
with HCV infection, but this does not negate possible
impairment of NK cell function with HCV infection. In
vitro, binding of HCV E2 to CD81 inhibits the functions of
cross-linked NK cells [14,15]. CD56+ NK cell proportion
was reduced among our subjects who cleared HCV despite
HIV co-infection, an observation that has no ready expla-
nation and may have appeared by chance.
Our study is limited by its cross-sectional design and anal-
ysis of PBMCs collected long after primary HCV and HIV
infections had occurred. We cannot define sequential
PBMC changes in relation to critical virologic events, such
as spontaneous clearance of HCV. Furthermore, the cells
that we detected in cryopreserved PBMCs may not be rep-
resentative of those in fresh PBMCs. Still, we did observe
the expected associations of CD4+ and CD8+ T cells with
HIV infection. These findings, our careful flow cytometry
methods, and our rigorous study design, with frequency
matching on age and random selection of subjects from a
large, well characterized cohort, probably offer a reliable
"snapshot" of PBMCs in hemophilic patients infected
with HCV alone or co-infected with HIV.
Conclusions
We found no association of cleared or chronic HCV infec-
tion with altered levels of CD4+ or CD8+ T cells, although
this does not negate the likely functional importance of
HCV-specific T-cell subpopulations in clearance of HCV
[16,17]. Subjects with high level, chronic HCV viremia,
but not those with cleared HCV infection, had reduced
CD19+ B-cell levels. Further studies need to clarify the
temporal sequence of B-cell changes with HCV chronicity
and associated clinical conditions.
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